Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   33145   clinical trials with a EudraCT protocol, of which   5359   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-002776-14
    Sponsor's Protocol Code Number:2012-002776-14
    National Competent Authority:Sweden - MPA
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2013-12-13
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSweden - MPA
    A.2EudraCT number2012-002776-14
    A.3Full title of the trial
    Ibuprofen versus mecillinam for uncomplicated cystitis in adult, non-pregnant women
    Ibuprofen versus mecillinam vid behandling av okomplicerad cystit hos vuxna ej-gravida kvinnor
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Treatment of cystitis in adult, non-pregnant women
    Behandling av cystit hos ej-gravida kvinnor
    A.4.1Sponsor's protocol code number2012-002776-14
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUniversity of Oslo, Faculty of medicine, Institute of Health and Society
    B.1.3.4CountryNorway
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportThe Norwegian Research Council
    B.4.2CountryNorway
    B.4.1Name of organisation providing supportThe National Centre of Emergency Primary Health Care
    B.4.2CountryNorway
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUniversity of Oslo
    B.5.2Functional name of contact pointIngvild Vik
    B.5.3 Address:
    B.5.3.1Street AddressAntibiotic Center of Primary Care
    B.5.3.2Town/ cityP.o. box 1130, Blindern, Oslo
    B.5.3.3Post code0318
    B.5.3.4CountryNorway
    B.5.4Telephone number004723487000
    B.5.6E-mailingvild.vik@medisin.uio.no
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ibuprofen ratiopharm
    D.2.1.1.2Name of the Marketing Authorisation holderRatiopharm
    D.2.1.2Country which granted the Marketing AuthorisationNorway
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIbuprofen
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPGastroenteral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIBUPROFEN
    D.3.9.1CAS number 15687-27-1
    D.3.9.4EV Substance CodeSUB08098MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Selexid
    D.2.1.1.2Name of the Marketing Authorisation holderLeo Pharma
    D.2.1.2Country which granted the Marketing AuthorisationNorway
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPGastroenteral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 32886-97-8
    D.3.9.3Other descriptive namePIVMECILLINAM HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB03884MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Uncomplicated cystitis in adult, non pregnant women, age 18-60.
    Okomplicerad cystit hos vuxna ej-gravida kvinnor i åldrarna 18-60
    E.1.1.1Medical condition in easily understood language
    Cystitis in women
    Cystit hos kvinnor
    E.1.1.2Therapeutic area Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.1
    E.1.2Level LLT
    E.1.2Classification code 10000699
    E.1.2Term Acute cystitis (excl in pregnancy)
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Although uncomplicated cystitis is considered to be a mild condition and mostly self limiting, most patients who see a doctor will be treated with antibiotics. Antibiotics are known to give a quick relief of symptoms and shorten the course of the condition by a few days.
    The aim of this study is to evaluate ibuprofen versus mecillinam in the treatment of uncomplicated cystitis in otherwise healthy, non-pregnant women.
    Our main objective is to see whether symptomatic treatment with ibuprofen is equally efficiant as treatment with mecillinam in this group.
    Okomplicerad cystit anses vara en mild och självläkande åkomma, trotts detta behandlas de flesta kvinnor som uppsöker läkare med antibiotika. Antibiotika brukar resultera i snabb symptomlindring samt förkortar tiden med symptom.
    Syftet med denna studie är att utvärdera effekten av ibuprofen versus mecillinam vid behandling av akut okomplicerad cystit hos vuxna, icke gravida kvinnor. Vi önskar att se om ibuprofen utgör ett likvärdigt behandlingsalternativ till mecillinam i denna patientgrupp.
    E.2.2Secondary objectives of the trial
    Will it take longer for the patients in the ibuprofen group to feel well? Are there more complications in the ibuprofen group compared to the mecillinam group? Are they more likely to develop an upper urinary tract infection? Are they more likely to develop a second uncomplicated cystitis within the four weeks of follow up? Are there more positive urine cultures in the ibuprofen group after two weeks?
    Tar det längre tid för patienterna i ibuprofengruppen att känna sig återställda? Finns där flera komplikationer i ibuprofengruppen jämfört med mecilinamgruppen? Har patienter i Ibuprofengruppen en ökad risk för att utveckla övre urinvägsinfektion? Eller en ökad risk för att utveckla ny okomplicerad cystit under uppföljningsperioden (4 veckor)? Är positiva kontrollodlingar (14 dagar) överrepresenterade i ibuprofengruppen
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Woman between 18 and 60 years of age.
    Dysuria and urinary frequency and/or urinary urgency.
    Ability to speak, understand and write Norwegian/Swedish/Danish and ability to give consent.
    Kvinnor mellan 18 och 60år, med dysuri och polakisuri och/eller frekventa trängningar, förmåga att förstå svenska språket samt ge skrivet samtycke

    E.4Principal exclusion criteria
    Pregnancy/breastfeeding child under one month of age
    Diabetes
    Kidney disease or use of the drug probenecid
    Clinical suspicion of pyelonefritis; fever, reduced general condition, upper back pain
    Vaginal symptoms such as discharge or irritation
    Severe abdominal pain
    Symptoms that have lasted for more than seven days
    One or more urinary tract infections within the lasts four weeks
    Permanent bladder catheter or use of bladder catheter within the last four weeks
    Use of antibiotics within the last two weeks
    Previous allergic reaction to penicillin
    Previous allergic reaction to ibuprofen, or worsening of asthma when taking NSAIDs
    Narrow oesophagus
    Severe gastritis or previous ulcer
    Anticoagulative treatment
    Ongoing use of steroids
    Use of immunosuppressant drugs
    Thrombocytopenia
    Heart insufficiency
    Severe psychiatric illness or dementia
    Severe drug addiction
    Unable to communicate in Norwegian, Swedish or Danish language
    Graviditet/amning av barn <1månad, diabetes, njursjukdom, genetisk aciduri, kliniks misstanke om njurbäckeninflammation, vaginala symptom såsom riklig flytning eller irritation, svår buksmärta, symptom > 7 dagar, urinvägsinfektion under de senaste 4 veckorna, permanent KAD eller KAD under de senaste 14 dagarna, antibiotika behandling under de senaste 2 veckorna, deltagande i annan klinisk studie under de 2 veckorna, tidigare njurbäckeninflammation, tidigare penicillinallergi, tidigare allergi mot ibuprofen eller försämring av astma på NSAID, esophagusstriktur, svår gastritt eller tidigare ulcus, pågående Probecid, kortison, Waran eller immunosupressivbehandling, trombocytopeni, ulcerös kolit samt Mb.Crohn, hjärtsvikt, svår psykisk åkomma eller demens, narkotikamissbruk, bristande kunskaper i svenska språket
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of patients who feel cured by day four as registered in the patient diary
    Andelen patienter som i dagböckerna uppgav att de kände sig återställda dag 4
    E.5.1.1Timepoint(s) of evaluation of this end point
    Four days
    Fyra dagar
    E.5.2Secondary end point(s)
    The patients’ symptom load with regard to specific symptoms.
    Proportion of patients who had a relapse of symptoms of uncomplicated cystitis within the study period.
    Proportion of patients who were in need of a secondary medical consult within the study period.
    Proportion of patients who developed an upper urinary tract infection (pyelonefritis).
    Proportion of patients who experienced severe adverse effects.
    Proportion of patients with a positive urine culture after two weeks.
    Patienternas symptomtyngd med avseende på specifika symptom
    Andelen patienter som upplevd återfall av cystitsymptom under studietiden
    Andelen patienter som sökt läkare för urinvägsrelaterade symptom under studietiden.
    Andelen patienter som utvecklad en övre urinvägsinfektion(pyelonefritt)
    Andelen patienter med upplevda allvarliga biverkningar
    Andelen patienter med positiv urinodling efter 14 dagar
    E.5.2.1Timepoint(s) of evaluation of this end point
    Four weeks
    Fyra veckor
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA2
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    We will end the trial when a sufficient number of patients have been included according to the power calculation, i.e. 400 patients in total, 200 in Oslo and 70at each of the other three study sites. End of trial is four weeks after the visit of the last subject undergoing the trial since the follow up of the subject is four weeks after inclusion in the trial.
    Vi avslutar studien när tillräckligt antal patienter inkluderats - enligt Powerberäkningen behöver 400 patienter inkluderas; 200 patienter i Oslo, och ca 200 från de övriga inkluderande studiecentra i Norge, Danmark samt Sverige. Datainsamlingen avslutas 4 veckor efter den senast inkluderade patienten (efter den senast inkluderade 4 -veckors kontroll)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 80
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state80
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 140
    F.4.2.2In the whole clinical trial 400
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ingen
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation EMA Oslo
    G.4.3.4Network Country Norway
    G.4 Investigator Network to be involved in the Trial: 2
    G.4.1Name of Organisation EMA Bergen
    G.4.3.4Network Country Norway
    G.4 Investigator Network to be involved in the Trial: 3
    G.4.1Name of Organisation University of Copenhagen, Dept of General Practice
    G.4.3.4Network Country Denmark
    G.4 Investigator Network to be involved in the Trial: 4
    G.4.1Name of Organisation University of Lund, Dept of General Practice SUS, Malmö, CRC
    G.4.3.4Network Country Sweden
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-04-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-03-04
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-Fri Aug 17 00:34:10 BST 2018 | 30 Churchill Place, Canary Wharf, London E14 5EU
    Legal notice
    EMA HMA